Skip to main content
SpringerLink
Log in

Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia

  • Clinical Trials
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Objective

To test whether treatment with fenofibrate decreases asymmetric dimethylarginine (ADMA) level in hypertriglyceridemic individuals.

Methods

In the present study, 45 subjects with hypertriglyceridemia were recruited to receive treatment with fenofibrate (200 mg/d). Serum concentrations of ADMA, malondialdehyde (MDA), nitric oxide (NO) and tumor necrosis factor-α (TNF-α) were measured. Endothelial function assessed by flow-mediated dilation (FMD) of the brachial artery was performed.

Results

Compared with control, serum levels of ADMA (0.47±0.05 μmol/L in control and 0.62±0.28 μmol/L in hypertriglyceridemic patients, P<0.01), MDA and TNF-α were markedly elevated, and the level of NO was significantly reduced, concomitantly with impaired endothelium-dependent vasodilation in individuals with hypertriglyceridemia. 8-week treatment with fenofibrate significantly reduced the elevated levels of ADMA (0.53±0.12 μmol/L, P<0.01), MDA and TNF-α, attenuated the decreased level of NO and improved endothelial function.

Conclusions

These results suggest that the beneficial effect of fenofibrate on the endothelium in hypertriglyceridemic individuals may be related to reduction of ADMA level.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig 1
Fig 2
Fig 3
Fig 4
Fig 5
Fig 6

Similar content being viewed by others

References

  1. Leiper J, Vallance P (1999) Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 43:542–548

    Article  PubMed  CAS  Google Scholar 

  2. Surdacki A, Nowicki M, Sandmann J, Tsikas D, Boeger RH, Bode-Boeger SM, Kruszelnicka-Kwiatkowska O, Kokot F, Dubiel JS, Froelich JC (1999) Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 33:652–658

    Article  PubMed  CAS  Google Scholar 

  3. Saitoh M, Osanai T, Kamada T, Matsunaga T, Ishizaka H, Hanada H, Okumura K (2003) High plasma level of asymmetric dimethylarginine in patients with acutely exacerbated congestive heart failure: role in reduction of plasma nitric oxide level. Heart Vessels 18:177–182

    Article  PubMed  Google Scholar 

  4. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I (2003) Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 166:279–284

    Article  PubMed  CAS  Google Scholar 

  5. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T (1999) Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99:1141–1146

    PubMed  CAS  Google Scholar 

  6. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC (2003) Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 24:1912–1919

    Article  PubMed  CAS  Google Scholar 

  7. Boger RH (2003) The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res 59:824–833

    Article  PubMed  CAS  Google Scholar 

  8. Okopien B, Cwalina L, Haberka M, Kowalski J, Zielinski M, Szwed Z, Kalina Z, Herman ZS (2002) Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia. Pol Merkuriusz Lek 13:465–469

    PubMed  Google Scholar 

  9. Vakkilainen J, Steiner G, Ansquer JC, Aubin F, Rattier S, Foucher C, Hamsten A, Taskinen MR, DAIS Group (2003) Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 107:1733–1737

    Article  PubMed  Google Scholar 

  10. Liang B, McMaster JC, Kroeger EA, Hatch GM, Mymin D, Dembinski T, Arthur G, Shen G, Man RY, Choy PC (2000) The effect of fenofibrate treatment on endothelium-dependent relaxation induced by oxidative modified low density lipoprotein from hyperlipidemic patients. Mol Cell Biochem 207:123–129

    Article  PubMed  CAS  Google Scholar 

  11. Yang TL, Chen MF, Luo BL, Yu J, Jiang JL, Li YJ (2004) Effect of fenofibrate on LDL-induced endothelial dysfunction in rats. Naunyn Schmiedeberg’s Arch Pharmacol 370:79–83

    CAS  Google Scholar 

  12. Chen BM, Xia LW, Zhao RQ (1997) Determination of N(G),N(G)-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci 692:467–471

    Article  CAS  Google Scholar 

  13. Bessman JD, Gardner FH (1983) Platelet size in thrombocytopenia due to sepsis. Surg Gynecol Obstet 156:177–180

    PubMed  CAS  Google Scholar 

  14. Feng Q, Lu X, Jones DL, Shen J, Arnold JM (2001) Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 104:700–704

    Article  PubMed  CAS  Google Scholar 

  15. Teppo AM, Maury CP (1987) Radioimmunoassay of tumor necrosis factor in serum. Clin Chem 33:2024–2027

    PubMed  CAS  Google Scholar 

  16. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340:1111–1115

    Article  PubMed  CAS  Google Scholar 

  17. Cooke JP (2000) Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20:2032–2037

    PubMed  CAS  Google Scholar 

  18. Stuhlinger MC, Oka RK, Graf EE, Schmolzer I, Upson BM, Kapoor O, Szuba A, Malinow MR, Wascher TC, Pachinger O, Cooke JP (2003) Endothelial dysfunction induced by hyperhomocyst(e)inemia: role of asymmetric dimethylarginine. Circulation 108:933–938

    Article  PubMed  CAS  Google Scholar 

  19. Paiva H, Laakso J, Lehtimaki T, Isomustajarvi M, Ruokonen I, Laaksonen R (2003) Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol 41:219–222

    Article  PubMed  Google Scholar 

  20. Fard A, Tuck CH, Donis JA, Sciacca R, Di Tullio MR, Wu HD, Bryant TA, Chen NT, Torres-Tamayo M, Ramasamy R, Berglund L, Ginsberg HN, Homma S, Cannon PJ (2000) Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes. Arterioscler Thromb Vasc Biol 20:2039–2044

    PubMed  CAS  Google Scholar 

  21. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P (2001) Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 38:111–116

    Article  PubMed  CAS  Google Scholar 

  22. Valkonen VP, Paiva H, Salonen JT, Lakka TA, Lehtimaki T, Laakso J, Laaksonen R (2001) Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358:2127–2128

    Article  PubMed  CAS  Google Scholar 

  23. Deplanque D, Gele P, Petrault O, Six I, Furman C, Bouly M, Nion S, Dupuis B, Leys D, Fruchart JC, Cecchelli R, Staels B, Duriez P, Bordet R (2003) Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci 23:6264–6271

    PubMed  CAS  Google Scholar 

  24. Murray-Rust J, Leiper J, McAlister M, Phelan J, Tilley S, Santa Maria J, Vallance P, McDonald N (2001) Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 8:679–683

    Article  PubMed  CAS  Google Scholar 

  25. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP (1999) Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99:3092–3095

    PubMed  CAS  Google Scholar 

  26. Saran R, Novak JE, Desai A, Abdulhayoglu E, Warren JS, Bustami R, Handelman GJ, Barbato D, Weitzel W, D'Alecy LG, Rajagopalan S (2003) Impact of vitamin E on plasma asymmetric dimethylarginine (ADMA) in chronic kidney disease (CKD): a pilot study. Nephrol Dial Transplant 18:2415–2420

    Article  PubMed  CAS  Google Scholar 

  27. Jiang JL, Li Ns NS, Li YJ, Deng HW (2002) Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 135:1175–1182

    Article  PubMed  CAS  Google Scholar 

  28. Jiang DJ, Jiang JL, Tan GS, Du YH, Xu KP, Li YJ (2003) Protective effects of daviditin A against endothelial damage induced by lysophosphatidylcholine. Naunyn Schmiedebergs Arch Pharmacol 367:600–606

    Article  PubMed  CAS  Google Scholar 

  29. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Boger SM (2000) LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 87:99–105

    PubMed  CAS  Google Scholar 

  30. Chan JR, Boger RH, Bode-Boger SM, Tangphao O, Tsao PS, Blaschke TF, Cooke JP (2000) Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol 20:1040–1046

    PubMed  CAS  Google Scholar 

  31. Cybulsky MI, Gimbrone MA (1991) Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 251:788–791

    Article  PubMed  CAS  Google Scholar 

  32. Boger RH, Bode-Boger SM, Tsao PS, Lin PS, Chan JR, Cooke JP (2000) An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 36:2287–2295

    Article  PubMed  CAS  Google Scholar 

  33. Malik J, Melenovsky V, Wichterle D, Haas T, Simek J, Ceska R, Hradec J (2001) Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial-FAT). Cardiovasc Res 52:290–298

    Article  PubMed  CAS  Google Scholar 

  34. Rival Y, Beneteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, Junquero D, Colpaert FC, Delhon A (2002) PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 435:143–151

    Article  PubMed  CAS  Google Scholar 

  35. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J (1999) PPARa activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99:3125–3131

    PubMed  CAS  Google Scholar 

  36. Dierkes J, Westphal S, Martens-Lobenhoffer J, Luley C, Bode-Boger SM (2004) Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration. Atherosclerosis 173:239–244

    Article  PubMed  CAS  Google Scholar 

  37. Yang TL, Chen MF, Luo BL, Xie QY, Li YJ (2005) Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity. Naunyn Schmiedeberg’s Arch Pharmacol 371:401–407

    Article  PubMed  CAS  Google Scholar 

  38. Sydow K, Schwedhelm E, Arakawa N et al (2003) ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res 57:244–252

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by a grant from State Education Commission, P.R. China. We are grateful to Dr. Liu Yue-Hui for the revision of English style.

Author information

Authors and Affiliations

  1. Department of Cardiovascular Medicine, Xiang-Ya Hospital, Central South University, Changsha, Hunan, 410008, China

    Tian-Lun Yang, Mei-Fang Chen, Xin Xia & Bai-Lin Luo

  2. Department of Pharmacology, School of Pharmaceutical Sciences, Central South University, Xiang-Ya Road 110#, Changsha, Hunan, 410078, China

    Yuan-Jian Li

Authors
  1. Tian-Lun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mei-Fang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xin Xia
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bai-Lin Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yuan-Jian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yuan-Jian Li.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, TL., Chen, MF., Xia, X. et al. Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia. Eur J Clin Pharmacol 62, 179–184 (2006). https://doi.org/10.1007/s00228-005-0095-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-005-0095-6

Keywords

Search

Navigation